Form 8-K - Current report:
SEC Accession No. 0001437749-24-026387
Filing Date
2024-08-13
Accepted
2024-08-13 16:11:07
Documents
16
Period of Report
2024-08-13
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K pbla20240813_8k.htm   iXBRL 8-K 34647
2 EXHIBIT 99.1 ex_713665.htm EX-99.1 222329
7 logo01.jpg GRAPHIC 9008
  Complete submission text file 0001437749-24-026387.txt   419115

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA pbla-20240813.xsd EX-101.SCH 3409
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE pbla-20240813_def.xml EX-101.DEF 11424
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE pbla-20240813_lab.xml EX-101.LAB 15310
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE pbla-20240813_pre.xml EX-101.PRE 11584
18 EXTRACTED XBRL INSTANCE DOCUMENT pbla20240813_8k_htm.xml XML 2829
Mailing Address 712 VISTA BLVD #305 WACONIA MN 55387
Business Address 712 VISTA BLVD #305 WACONIA MN 55387 9524791196
Panbela Therapeutics, Inc. (Filer) CIK: 0001029125 (see all company filings)

EIN.: 870543922 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39468 | Film No.: 241201547
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)